Benitec Biopharma Stock (NASDAQ:BNTC)
Previous Close
$10.40
52W Range
$2.69 - $12.89
50D Avg
$9.87
200D Avg
$7.76
Market Cap
$211.62M
Avg Vol (3M)
$30.18K
Beta
0.88
Div Yield
-
BNTC Company Profile
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
BNTC Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. |
| ONCR | Oncorus, Inc. |
| VIRI | Virios Therapeutics, Inc. |
| NXTC | NextCure, Inc. |
| APLM | Apollomics, Inc. |
| BPTH | Bio-Path Holdings, Inc. |
| CAPR | Capricor Therapeutics, Inc. |
| DFFN | CervoMed Inc. |
| LABP | Landos Biopharma, Inc. |
| SGTX | Sigilon Therapeutics, Inc. |
| EFTR | eFFECTOR Therapeutics, Inc. |
| CBIO | Gyre Therapeutics, Inc. |
| ZURA | Zura Bio Limited |
| ALRN | Aileron Therapeutics, Inc. |